PMID- 38213906
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240113
IS  - 2472-1972 (Electronic)
IS  - 2472-1972 (Linking)
VI  - 8
IP  - 2
DP  - 2024 Jan 5
TI  - Once-weekly Insulin Icodec Versus Once-daily Long-acting Insulin for Type II 
      Diabetes: A Meta-analysis of Randomized Controlled Trials.
PG  - bvad177
LID - 10.1210/jendso/bvad177 [doi]
LID - bvad177
AB  - BACKGROUND: Insulin icodec is a novel basal insulin analog with once-weekly 
      subcutaneous administration. We aim to estimate the efficacy and safety of 
      insulin icodec vs long-acting insulin (insulin glargine and degludec) in type II 
      diabetic patients. METHODS: We conducted a systematic review and meta-analysis 
      synthesizing randomized controlled trials (RCTs), which were retrieved by 
      systematically searching PubMed, Web of Science, SCOPUS, and Cochrane through May 
      29, 2023. We used RevMan V. 5.4 to pool dichotomous data using risk ratio (RR) 
      and continuous data using mean difference (MD) with a 95% confidence interval 
      (CI). Our primary outcome was glycated hemoglobin (HbA1C) change. RESULTS: We 
      included 7 RCTs with a total of 3183 patients. Insulin icodec was associated with 
      significantly decreased HbA1C (MD: -0.15 with 95% CI [-0.24, -0.06], P = .002) 
      and increased percentage of time with glucose in range (TIR) (MD: 4.06 with 95% 
      CI [2.06, 6.06], P = .0001). However, insulin icodec was associated with 
      increased body weight (MD: 0.57 with 95% CI [0.45, 0.70], P = .00001). Also, 
      there was no difference regarding any serious adverse events (AEs) (RR: 0.96 with 
      95% CI [0.76, 1.20], P = .7) or AEs leading to withdrawal (RR: 1.54 with 95% CI 
      [0.84, 2.82], P = .16). However, insulin icodec was associated with increased any 
      AEs incidence (RR: 1.06 with 95% CI [1.01, 1.12], P = .02). CONCLUSION: Insulin 
      icodec was associated with decreased HbA1C, increased TIR, with similar 
      hypoglycemic and serious AEs. However, it was also associated with increased body 
      weight and the incidence of any AEs.
CI  - (c) The Author(s) 2023. Published by Oxford University Press on behalf of the 
      Endocrine Society.
FAU - Abuelazm, Mohamed
AU  - Abuelazm M
AUID- ORCID: 0000-0002-2514-0689
AD  - Faculty of Medicine, Tanta University, Tanta 31111, Egypt.
FAU - Ibrahim, Ahmed A
AU  - Ibrahim AA
AD  - Faculty of Medicine, Menoufia University, Menoufia 32511, Egypt.
FAU - Khlidj, Yehya
AU  - Khlidj Y
AD  - Faculty of Medicine, Algiers University, Algiers 44002, Algeria.
FAU - Badr, Amr
AU  - Badr A
AD  - Department of Cardiology, Banha Teaching Hospital, Banha 13511, Egypt.
FAU - Amin, Ahmed Mazen
AU  - Amin AM
AD  - Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt.
FAU - Elzeftawy, Mohamad A
AU  - Elzeftawy MA
AD  - Faculty of Medicine, Tanta University, Tanta 31111, Egypt.
FAU - Gowaily, Ibrahim
AU  - Gowaily I
AD  - Faculty of Medicine, Tanta University, Tanta 31111, Egypt.
FAU - Elsaeidy, Ahmed Saad
AU  - Elsaeidy AS
AD  - Faculty of Medicine, Banha University, Banha 13518, Egypt.
FAU - Abdelazeem, Basel
AU  - Abdelazeem B
AUID- ORCID: 0000-0002-2919-6196
AD  - Department of Cardiology, West Virginia University, Morgantown, WV 26505, USA.
AD  - Department of Internal Medicine, Michigan State University, East Lansing, MI 
      48824, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20231228
PL  - United States
TA  - J Endocr Soc
JT  - Journal of the Endocrine Society
JID - 101697997
PMC - PMC10783254
OTO - NOTNLM
OT  - analysis
OT  - diabetes
OT  - glucose
OT  - insulin
OT  - review
EDAT- 2024/01/12 06:43
MHDA- 2024/01/12 06:44
PMCR- 2023/12/28
CRDT- 2024/01/12 03:48
PHST- 2023/10/09 00:00 [received]
PHST- 2024/01/12 06:44 [medline]
PHST- 2024/01/12 06:43 [pubmed]
PHST- 2024/01/12 03:48 [entrez]
PHST- 2023/12/28 00:00 [pmc-release]
AID - bvad177 [pii]
AID - 10.1210/jendso/bvad177 [doi]
PST - epublish
SO  - J Endocr Soc. 2023 Dec 28;8(2):bvad177. doi: 10.1210/jendso/bvad177. eCollection 
      2024 Jan 5.